Johnson & Johnson
Pharmaceutical / Medical Devices / HealthcareFounded 1886- Updated June 2026
Reviewed by Swet Parvadiya
Last reviewed: June 2026
CorpDigest
Johnson & Johnson
Company History
Founded 1886 in New Brunswick, New Jersey
Last reviewed: 2026-06-03 · By Swet Parvadiya
Johnson & Johnson is a Pharmaceutical / Medical Devices / Healthcare company with $88.8B in 2024 revenue and 132K employees worldwide. Johnson & Johnson occupies a singular position in American healthcare: a company whose institutional history spans the introduction of sterile surgical dressings before antiseptic surgery was standard practice in American hospitals, the invention of the ready-to-use adhesive bandage in 1921, the creation of the modern corporate responsibility framework in 1943, the definitive crisis management case study in 1982, and the invention of immunology blockbusters and CAR-T cell therapies in the twenty-first century. No other company has been continuously operating at the frontier of healthcare innovation for nearly 140 years across that range of product categories and technological generations. The 2023 Kenvue spinoff represents J&J's most consequential strategic self-transformation in its modern history — the deliberate surrender of the consumer brand heritage that defined its public identity for a century in order to concentrate all organizational resources on the highest-value therapeutic and device innovation opportunities. The resulting enterprise — focused entirely on Innovative Medicine and MedTech — carries a higher margin profile, a more pharmaceutical-intensive growth trajectory, and a more concentrated strategic risk than the legacy diversified J&J. The company's institutional character is defined as much by its Credo as by its product portfolio. Written by Robert Wood Johnson II in 1943 with a specificity and values prioritization that was unusual in corporate governance of that era, the Credo has served as J&J's ethical north star across multiple generations of leadership and competitive environments. Its most famous test — the 1982 Tylenol recall — demonstrated that the Credo's patient-first framework was operationally real rather than merely aspirational, establishing institutional trust with healthcare professionals, consumers, and capital market participants that has compounded for four decades. From the Raritan River factory of 1886 to the global pharmaceutical and device enterprise of 2025, J&J's 139-year commercial trajectory represents the longest-sustained commitment to healthcare innovation in American corporate history.
Robert Wood Johnson I was the visionary and primary strategic architect of Johnson & Johnson's founding concept. His central insight — that Joseph Lister's antiseptic surgery principles would eventually be adopted across American medicine and that a factory-scale supplier of sterile surgical materials would be positioned advantageously ahead of that transition — proved correct within a decade of the company's founding. As American surgery's adoption of antiseptic technique accelerated through the late 1880s and 1890s, J&J's prepared position as a scaled, quality-controlled manufacturer of sterile dressings and sutures created first-mover advantages in hospital supply relationships that the company held for generations. Johnson I also demonstrated early instincts for healthcare professional education as a marketing platform, overseeing the 1888 publication of Modern Methods of Antiseptic Wound Treatment — a physician reference guide that simultaneously taught antiseptic technique and positioned J&J's products as the recommended materials for implementing it. Under his leadership, J&J expanded beyond surgical dressings into dental floss, baby powder, and early pharmaceutical preparations, establishing the diversified healthcare product base that would define the company's commercial strategy throughout the twentieth century. He was succeeded by his son Robert Wood Johnson II, who would transform J&J into the global diversified healthcare enterprise and write the Credo that became the company's lasting ethical foundation.
James Wood Johnson's contribution to J&J's founding was primarily operational: the day-to-day management of a manufacturing enterprise that needed to produce consistently sterile surgical materials while scaling production to meet the rapidly expanding demand from American hospitals and physicians adopting antiseptic surgical techniques. The technical challenge of factory-scale sterilization in the 1880s — before modern autoclave technology was widely available, and before the bacteriological science underlying sterilization was fully understood — required both practical manufacturing discipline and a commitment to quality control standards that exceeded the norm in consumer goods manufacturing of that era. James Wood Johnson's management of the production operations established the quality-first manufacturing culture that J&J maintained as a competitive differentiator across generations of product lines far removed from the original sterile gauze business. His sons — particularly James Wood Johnson II — continued his leadership of the company in the early twentieth century, including overseeing the launch of the Band-Aid brand adhesive bandage in 1921, which became the company's most recognizable consumer product for a century before its transfer to Kenvue in 2023.
Edward Mead Johnson's tenure at Johnson & Johnson was the shortest of the three brothers, but his departure to pursue the infant nutrition and pediatric dietary supplement market established a separate commercial legacy that endured for well over a century. Mead Johnson, the company he founded after leaving J&J, developed nutritional formulas for infants and young children at a time when pediatric nutrition science was in its early development — a category that grew substantially through the twentieth century as infant formula adoption expanded globally and nutritional science generated evidence for specific dietary requirements in pediatric development. Edward Mead Johnson's commercial instinct for pediatric health needs represented an extension of the broader Johnson family interest in healthcare products for vulnerable populations — an interest that J&J itself would also develop through the Johnson's Baby product line that became one of its most globally recognized consumer franchises. The Mead Johnson business eventually became part of Bristol-Myers Squibb before being acquired by Reckitt Benckiser in 2017 for approximately $16.6 billion, demonstrating the enduring commercial value of the pediatric nutrition platform that Edward built from his post-J&J entrepreneurial departure.
Brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson established Johnson & Johnson in New Brunswick, New Jersey in 1886, beginning operations in a rented former factory with fewer than 15 employees producing ready-to-use sterile surgical dressings. The founding was inspired by Robert's 1876 exposure to Joseph Lister's antiseptic surgery principles and his recognition that American medicine's eventual adoption of antiseptic technique would require a reliable factory-scale supplier of sterilized surgical materials.
J&J published Modern Methods of Antiseptic Wound Treatment, one of the first practical physician reference guides to Listerian antiseptic surgical technique in the United States. The pamphlet was distributed to hospitals and physicians across the country, simultaneously advancing public health by accelerating antiseptic surgery adoption and commercially positioning J&J's sterile dressings and sutures as the recommended materials for implementing the techniques described — establishing the healthcare professional education-and-product-recommendation template that pharmaceutical and device companies still use today.
J&J cotton buyer Earle Dickson invented the ready-to-use adhesive bandage in 1920 after repeatedly improvising wound coverings for his accident-prone wife Josephine. The product was commercially launched under the Band-Aid brand name in 1921, initially selling its first-year production run primarily to the Boy Scouts of America before growing into one of the most globally recognized consumer product brand names of the twentieth century. Band-Aid transferred to Kenvue as part of J&J's consumer health spinoff in 2023.
Robert Wood Johnson II wrote the J&J Credo in 1943, one year before the company's NYSE initial public offering, establishing a formal hierarchy of corporate responsibilities: first to patients and consumers, second to employees, third to communities, and fourth to shareholders. The Credo's explicit deprioritization of shareholder interests relative to patients and communities was unusual in 1943 corporate governance and became J&J's most consequential institutional document — operationally tested most visibly in the 1982 Tylenol recall, where CEO James Burke spent $100 million on a voluntary recall based on Credo principles despite bearing no legal responsibility for the tampering.
J&J acquired McNeil Laboratories in 1959, adding acetaminophen-based pain relief formulations that McNeil had developed, including the children's liquid formulation marketed as TYLENOL. J&J expanded Tylenol into adult over-the-counter analgesics, building it into the dominant U.S. Acetaminophen brand before the 1982 tampering crisis temporarily collapsed its market position — and before J&J's crisis response demonstrated that brand equity is recoverable when consumer trust is prioritized above short-term commercial considerations.
J&J acquired Janssen Pharmaceutica in 1961, the Belgian pharmaceutical company founded by scientist Paul Janssen — one of the most prolific drug discoverers in pharmaceutical history, credited with more than 80 medications including haloperidol (antipsychotic), fentanyl (opioid analgesic), and ketoconazole (antifungal). The Janssen acquisition provided J&J with serious pharmaceutical research capabilities for the first time and established the Janssen R&D organization that would eventually develop Risperdal, Remicade, Stelara, Darzalex, Carvykti, and the majority of J&J's modern pharmaceutical blockbuster franchise.
Seven Chicago-area deaths from cyanide-laced Tylenol capsules tampered with on retail shelves prompted CEO James Burke to recall approximately 31 million bottles of Tylenol worth $100 million at retail — despite J&J bearing no manufacturing responsibility — guided by the J&J Credo's patient-first framework. The recall created tamper-evident packaging standards that became mandatory across the industry and demonstrated that transparent, consumer-safety-first crisis response could restore brand equity: Tylenol recovered to category leadership within one year and became one of J&J's most commercially important brands for three decades.
J&J acquired Centocor in 1999 for approximately $4.9 billion, adding Remicade (infliximab) — a chimeric anti-TNF monoclonal antibody for rheumatoid arthritis, Crohn's disease, and multiple inflammatory conditions — which became one of the world's best-selling drugs and generated peak annual revenues exceeding $6 billion globally. The Centocor acquisition established J&J's immunology pharmaceutical franchise and demonstrated the company's strategic approach to acquiring externally developed breakthrough biologics and scaling them through J&J's global commercial infrastructure.
J&J completed the acquisition of Synthes Inc. For approximately $21.3 billion in 2011, adding the global leader in orthopaedic trauma fixation devices and spine surgery systems to J&J's existing DePuy orthopaedic joint reconstruction franchise. The combined DePuy Synthes entity became the world's largest orthopaedic medical device company by revenue, giving J&J comprehensive coverage across joint reconstruction, trauma, spine, and sports medicine — and establishing a scale advantage in orthopaedics that has sustained competitive leadership for more than a decade.
J&J completed the acquisition of Abiomed, Inc. For approximately $16.6 billion in January 2022, adding the Impella family of percutaneous mechanical circulatory support devices — the world's smallest heart pumps, used in cardiogenic shock and high-risk interventional cardiology procedures. The Abiomed acquisition added J&J's highest-growth MedTech asset, as Impella adoption in cardiogenic shock remains substantially below the eligible patient population, and clinical evidence supporting Impella's outcomes benefit continues to expand through ongoing registry and trial programs.
J&J completed the spinoff of its consumer health segment as Kenvue, Inc. (NYSE: KVUE) through an IPO in May 2023, followed by an exchange offer completed in August 2023 that distributed remaining J&J-held Kenvue shares to J&J shareholders. The transaction transferred Tylenol, Band-Aid, Neutrogena, Johnson's Baby, Listerine, Aveeno, Nicorette, and dozens of other consumer brands to an independently traded public company, transforming J&J into a pure-play pharmaceutical and medical device enterprise for the first time in its modern corporate history.
J&J completed the acquisition of Shockwave Medical, Inc. For approximately $13.1 billion in 2024, adding intravascular lithotripsy technology for treating severely calcified coronary artery disease — a rapidly growing clinical application with no comparable competing system. In the same year, J&J proposed a $6.475 billion comprehensive talc litigation settlement requiring approval from a supermajority of current and future claimants, representing the company's attempt to finally resolve a decade of talc asbestos litigation through a mass tort settlement framework after two failed Texas Two-Step bankruptcy approaches were rejected by federal courts.
Acquired the Belgian pharmaceutical company founded by Paul Janssen to enter the prescription drug market and diversify beyond consumer products and surgical supplies.
Acquired the Swiss orthopedic trauma device maker to become the world's largest orthopedics company, combining Synthes's trauma expertise with J&J's existing joint replacement business (DePuy).
Acquired the Swiss biotech specializing in pulmonary arterial hypertension (PAH) treatments to strengthen J&J's cardiovascular portfolio and add high-growth specialty pharmaceuticals.
Acquired the maker of the Impella heart pump to strengthen J&J's cardiovascular intervention capabilities and enter the rapidly growing mechanical circulatory support market.